Farahbakhshian, Sepehr http://orcid.org/0000-0002-8479-2775
Ayyagari, Rajeev
Barczak, Daniel S.
Gill, Simerpal K.
Tang, Wenxi
Kulalert, Thomas
Jenkins, Madeline
Spalding, William
Funding for this research was provided by:
Shire Development LLC, a member of the Takeda group of companies, Lexington, MA, USA
Article History
Accepted: 17 March 2021
First Online: 15 April 2021
Declarations
:
: This study was supported by funding from Shire Development LLC, a member of the Takeda group of companies, Lexington, MA, USA. Open access was funded by Shire Development LLC, a member of the Takeda group of companies, Lexington, MA, USA.
: Sepehr Farahbakhshian, Daniel S. Barczak, and William Spalding are employees of Takeda Pharmaceuticals USA and hold Takeda stock. Simerpal K. Gill is an employee of Takeda Canada Inc. and holds Takeda stock. Rajeev Ayyagari, Wenxi Tang, Thomas Kulalert, and Madeline Jenkins are employees of Analysis Group, Inc., which was funded by Shire, a member of the Takeda group of companies, to conduct this research.
: This study did not involve prospective data collection; therefore, institutional review board approval was not required. Patient data were deidentified in accordance with the patient confidentiality requirements of the Health Insurance Portability and Accountability Act of 1996. A summary of the final study report was provided to the appropriate regulatory bodies in compliance with appropriate guidelines.
: Not applicable.
: Not applicable.
: The data that support the findings of this study are available from the IBM<sup>®</sup> MarketScan<sup>®</sup> Commercial Databases, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available.
: All authors contributed to the development of the manuscript, reviewed it at each stage of development, and approved the final draft for submission to <i>CNS Drugs</i>.